Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEACE-4: Acetylsalicylic Acid and Atorvastatin in CRPC
NCT03819101Phase 3Recruiting
- Sponsor
- Gustave Roussy
- Start
- Jun 2019
- Primary completion
- Mar 2042
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of aspirin and atorvastatin in castration-resistant prostate cancer (CRPC) (4 arms), sponsored by Gustave Roussy. Primary endpoint: Overall Survival at 15 years. Started Jun 2019; status: recruiting.
02
Drugs
aspirinatorvastatin
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT03819101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03819101.